Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

David J. Propper

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4274-5460; OpenAlex author ID A5040991512, A5158907393. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 10

  1. Corrigendum to "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer" [… Co-author DOI 10.1016/j.redox.2026.104395↗
  2. Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2025.103895↗
  3. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Last author DOI 10.1186/s12885-024-13333-z↗
  4. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
  5. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  6. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Last author DOI 10.1038/s41467-020-18636-w↗
  7. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2018-316595↗
  8. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.495↗
  9. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an … Co-author DOI 10.1016/s1470-2045(14)70236-0↗
  10. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2011.10.017↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haiyong Han · 3 shared papers, 2023–2026 · strength 0.56
  2. Erkut Hasan Borazanci · 3 shared papers, 2023–2026 · strength 0.56
  3. Daniel D. Von Hoff · 3 shared papers, 2023–2026 · strength 0.56
  4. Michael T. Barrett · 3 shared papers, 2023–2026 · strength 0.56
  5. Gayle Jameson · 2 shared papers, 2025–2026 · strength 0.44
  6. Hemant Mahendrakumar Kocher · 3 shared papers, 2019–2025 · strength 0.36
  7. Ronald M. Evans · 2 shared papers, 2023–2025 · strength 0.32
  8. Pippa G. Corrie · 3 shared papers, 2014–2025 · strength 0.29
  9. Christine Hughes · 2 shared papers, 2020–2025 · strength 0.28
  10. Fieke E. M. Froeling · 2 shared papers, 2020–2025 · strength 0.28
  11. Debashis Sarker · 2 shared papers, 2020–2025 · strength 0.28
  12. Bristi Basu · 3 shared papers, 2018–2020 · strength 0.22
  13. Joshua D. Rabinowitz · 1 shared paper, 2025 · strength 0.20
  14. Claude Chelala · 1 shared paper, 2025 · strength 0.19
  15. Khurum Hayat Khan · 1 shared paper, 2025 · strength 0.19
  16. David Kuang-Fu Chang · 1 shared paper, 2025 · strength 0.19
  17. Mairead Geraldine McNamara · 1 shared paper, 2025 · strength 0.19
  18. Alan Anthoney · 3 shared papers, 2014–2020 · strength 0.16
  19. Daniel H. Palmer · 2 shared papers, 2018–2020 · strength 0.14
  20. Aarthi Gopinathan · 2 shared papers, 2018–2020 · strength 0.14
  21. David Arthur Tuveson · 2 shared papers, 2018–2020 · strength 0.14
  22. Duncan Ian Jodrell · 2 shared papers, 2018–2020 · strength 0.14
  23. Corina E. Antal · 1 shared paper, 2023 · strength 0.12
  24. Jan C. Lumibao · 1 shared paper, 2023 · strength 0.12
  25. Nicole M. Sodir · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.